BSSPlus Versus Lactated Ringer's for Phacoemulsification

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: surgerycongenitalsolutionpresence oftraumatic
  Phrases that lowered it: patients with20criteria patientstrial todensity
• Sponsor's past termination rate: 5.7% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 42.9% (raises risk) · Drug's FDA history
• Responsible party: not given (raises risk) · Design
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 38 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 50 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 7 (lowers risk) · Drug's FDA history
• Keywords listed: 5 (lowers risk) · Design
• Sponsor's past trials: 35 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 2 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Intracameral Steroids During Phacoemulsification on the Cornea NCT05271058 · started 2019 · scored riskier than 10% of active trials completed
• Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco NCT04396301 · started 2019 · scored riskier than 12% of active trials completed
• Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery NCT02101359 · started 2011 · scored riskier than 7% of active trials completed
• Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation NCT01218737 · started 2009 · scored riskier than 7% of active trials completed
• KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children NCT03596723 · started 2018 · scored riskier than 14% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.